Full Description
Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics: post-therapy imaging; fibroblast-activation-protein inhibitors (FAPI) theragnostics; and more.
Provides in-depth clinical reviews on theragnostics, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
In this issue of PET Clinics, guest editors Drs. Andrei Iagaru and Heather A. Jacene bring their considerable expertise to the topic of Theragnostics. Top experts in the field discuss neuroendocrine tumors: beta-labeled peptides; prostate-specific membrane antigen: interpretation criteria, standardized reporting and the use of artificial intelligence; prostate cancer (gastrin-releasing peptide receptor); selective internal radiation therapy; future directions in theragnostics; and more.
Contents
Alpha and Beta Radiation for Theragnostics
Neuroendocrine Tumors: Diagnostics
Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
Prostate-specific Membrane Antigen: Diagnostics
Prostate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine Learning
Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals
Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals
Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years
Treatment Response Imaging in Prostate Cancer
Hepatic Radioembolization: A Multistep Theragnostic Procedure
